5 days ago · Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: ... Full Year and Q4 2024 results clinical trials appendix. PDF 2,467KB Explore our clinical trials appendix. Adrian Kemp Company Secretary AstraZeneca PLC . tags. Corporate and financial

5 days ago · On Thursday 6 February 2025 we announced our Full Year and Q4 2024 results. An accompanying webcast for investors and analysts took place at 11:00 UK time. ... This website is intended for people seeking information on AstraZeneca's worldwide business. Our country sites can be located in the AZ Network. Veeva ID: Z4-68564 Date of next review ...

Accelerating AstraZeneca’s strategic and financial development: AstraZeneca to acquire Alexion

4 days ago · Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% respectively. We also ...

4 days ago · Financial performance for FY 2024 (Growth numbers at constant exchange rates) Total Revenue up 21% to $54,073m, driven by a 19% increase in Product Sales, continued growth of partnered...

4 days ago · Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% respectively. We also...

5 days ago · Q4 2024 Results Conference call and webcast for investors and analysts 06 February 2025. 2 ... AstraZeneca credit ratings: Moody’s: short-term rating P-1, long -term rating A2, outlook positive. S&P Global Ratings: short - term rating A -1, long -term rating A+, outlook stable. 4. If foreign exchange rates for February 2025 to December 2025 ...

4 days ago · Total Revenue Growth: Up 21% for the full year 2024. Core EPS Growth: Increased by 19% in 2024. Core Operating Expense Growth: Increased by 14% in 2024. China Revenue Growth: Increased by 11% for ...

4 days ago · Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.

4 days ago · We also delivered important pipeline advancements with nine high value pivotal trials readouts in 2024. Combined, these trials represent over $5 billion in non-risk adjusted peak year revenue.